Sweet's Syndrome |
Sweet’s syndrome is a relatively unusual but not rare dermatologic condition. It demonstrates a female prevalence; occurring about four times more commonly in women than men. The exact mechanism underlying Sweet’s syndrome is not known at this time. One of the current hypotheses equates the disease to the body developing a hypersensitivity reaction to an underlying infection, autoimmune disease, medication or cancer. The role of the neutrophil, which is a specialized form of white blood cell, in Sweet’s syndrome is thought to be an inappropriate response to cellular signals known as cytokines and growth factors. When present in excess amounts, cells like neutrophils will respond to theses signals and infiltrate the skin leading the characteristic rash.
Criteria for the diagnosis of Sweet’s syndrome include 2 major criteria and 4 minor criteria. To confirm the diagnosis, both major and 2 additional minor criteria must be met. They include: Major
Minor
Sweet’s syndrome in and of itself is a benign condition. If left alone, the lesions will resolve spontaneously but may recur in up to 30% of patients. If the disease is secondary to an underlying disease, treatment of the primary condition is recommended. The traditional therapy for Sweet’s syndrome is oral prednisone at doses of 0.5-1.0mg/kg/day for 4-6 weeks. Alternatives to prednisone include dapsone, potassium iodine and colchicine.
|
2/27/2018MACRA/MIPS Update
10/12/2017Foundation for Osteopathic Dermatology
7/6/2016Disclosure to members regarding CME activities
4/3/2014The Burning Truth
12/19/2013Osteopathic Training Statement
10/9/2018 » 10/13/2018
2018 AOCD Fall Current Concepts in Dermatology Meeting
4/9/2019 » 4/13/2019
2019 AOCD Spring Current Concepts in Dermatology Meeting
9/24/2019 » 9/28/2019
2019 AOCD Fall Current Concepts in Dermatology
2/19/2020 » 2/22/2020
2020 AOCD Spring Current Concepts in Dermatology
2/24/2021 » 2/27/2021
2021 AOCD Spring Current Concepts in Dermatology